|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 294.82 USD | -1.77% |
|
+2.91% | +56.51% |
| 01:34pm | RBC Adjusts PT on Ligand Pharmaceuticals to $345 From $340, Maintains Outperform Rating | MT |
| 08-06 | Ligand Pharmaceuticals Incorporated, Q2 2026 Earnings Call, Aug 06, 2026 |
Chart: Technical Analysis
Technical analysis trends
| Short Term | Mid-Term | Long Term | |
|---|---|---|---|
| Trend | Bearish | Bullish | Bullish |
| Resistance | 305.47 | 322.61 | 319.55 |
| Spread/Res. | -3.13% | -8.28% | -7.40% |
| Spread/Supp. | +2.91% | +25.44% | +27.65% |
| Support | 287.54 | 235.89 | 231.82 |
MarketScreener's Technical Analysis Ratings
| Short Term Timing | |
|---|---|
| Middle Term Timing | |
| Long Term Timing | |
| RSI | |
| Bollinger Spread | |
| Unusual Volumes |
- Stock Market
- Stocks
- LGND Stock
- Charts Ligand Pharmaceuticals Incorporated
Select your edition
All financial news and data tailored to specific country editions
